Usnoflast: A Cutting-Edge NLRP3 Inhibitor Attenuates Colonic Inflammation Across Diverse Immunopathology.

NLR (Nod-like receptor) family pyrin domain containing protein 3 (NLRP3) inflammasome activation is key component of innate immune response and is implicated in many autoimmune conditions. Usnoflast is a novel, selective NLRP3-inflammasome inhibitor and is currently in Phase II for various indications including Ulcerative colitis. Here, we report the effect of usnoflast in several experimental models of intestinal inflammation, some of them for the first time for any NLRP3 inhibitor, which involves both innate and adaptive immune mechanisms. Usnoflast suppressed lipopolysaccharide (LPS), and ATP induced interleukin (IL)-1β and IL-18 production in vivo with ID50 of 0.18 and 0.13 mg/kg indicating a potent inhibition of NLRP3 inflammasome activation. Usnoflast treatment ameliorated inflammation induced by dextran sodium sulfate (DSS) which was associated with suppression of NLRP3 target genes IL-1β and 18 in the colon tissues. Microarray analysis of colon tissues revealed modulation of several genes involved in biological processes such as inflammatory response, neutrophil chemotaxis, innate immune response, which were markedly altered by the treatment. Furthermore, for the first time, an NLRP3 inhibitor was evaluated in Salmonella Typhimurium induced enterocolitis where, usnoflast treatment was able to prevent colonic inflammation. Moreover, usnoflast treatment was able to suppress the TNBS and chronic DSS-induced colon inflammation, which are diseases driven by cell mediated immunity involving either T helper (Th)-1 or a mixed Th1 and Th2 cell types. These data clearly demonstrate the therapeutic potential of usnoflast against intestinal inflammation involving diverse immunopathogenesis.

• Publication year

  2025

• Venue

  European Journal of Pharmacology

• Publication date

  2025-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ejphar.2025.178117PMID 40912514
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson's disease.

  2024cited by this paper
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY‐IL1 in Three Patients with Cryopyrin‐Associated Periodic Syndromes

  2023cited by this paper
• A randomized, double‐blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis

  2023cited by this paper
• Treatment of Ulcerative Colitis by Cationic Liposome Delivered NLRP3 siRNA

  2023cited by this paper
• Inhibition of NLRP3 attenuates sodium dextran sulfate-induced inflammatory bowel disease through gut microbiota regulation

  2023cited by this paper
• Histones of Neutrophil Extracellular Traps Directly Disrupt the Permeability and Integrity of the Intestinal Epithelial Barrier.

  2023cited by this paper
• CXCL13 is elevated in inflammatory bowel disease in mice and humans and is implicated in disease pathogenesis

  2022cited by this paper
• NLRP3 Inflammasome Inhibitor OLT1177 Suppresses Onset of Inflammation in Mice with Dextran Sulfate Sodium-Induced Colitis

  2021cited by this paper
• Excessive deubiquitination of NLRP3-R779C variant contributes to very-early-onset inflammatory bowel disease development.

  2020cited by this paper
• Identification of differentially expressed genes in ulcerative colitis and verification in a colitis mouse model by bioinformatics analyses

  2020cited by this paper
• The loss of tolerance to CHI3L1 - A putative role in inflammatory bowel disease?

  2019cited by this paper
• Role of NLRP3 inflammasome in inflammatory bowel diseases

  2019cited by this paper
• A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation

  2018cited by this paper
• Formononetin Administration Ameliorates Dextran Sulfate Sodium-Induced Acute Colitis by Inhibiting NLRP3 Inflammasome Signaling Pathway

  2018cited by this paper
• Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation

  2017cited by this paper
• Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

  2017cited by this paper
• Cellular and molecular regulation of innate inflammatory responses

  2016cited by this paper
• NLRP3 inflammasome has a protective effect against oxazolone-induced colitis: a possible role in ulcerative colitis

  2016cited by this paper
• The cell surface receptor Slamf6 modulates innate immune responses during Citrobacter rodentium-induced colitis.

  2015cited by this paper
• Angiogenesis in Inflammatory Bowel Disease

  2015cited by this paper
• Experimental Models of Inflammatory Bowel Diseases

  2015cited by this paper
• Dextran Sulfate Sodium (DSS)‐Induced Colitis in Mice

  2014cited by this paper
• IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells

  2012cited by this paper
• Innate immune response to Salmonella typhimurium, a model enteric pathogen

  2012cited by this paper
• Protective and Aggravating Effects of Nlrp3 Inflammasome Activation in IBD Models: Influence of Genetic and Environmental Factors

  2012cited by this paper
• Temporal genomewide expression profiling of DSS colitis reveals novel inflammatory and angiogenesis genes similar to ulcerative colitis.

  2011cited by this paper
• Regulation of adaptive immunity by the NLRP3 inflammasome.

  2011cited by this paper
• Differential Expression of NLRP3 among Hematopoietic Cells

  2011cited by this paper
• Anti-inflammatory intestinal activity of Abarema cochliacarpos (Gomes) Barneby & Grimes in TNBS colitis model.

  2010cited by this paper
• Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases.

  2010cited by this paper
• Inhalation of Carbon Monoxide Ameliorates TNBS-Induced Colitis in Mice Through the Inhibition of TNF-α Expression

  2010cited by this paper
• Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome

  2010cited by this paper
• NOD-like receptors: role in innate immunity and inflammatory disease.

  2009cited by this paper
• Therapeutic Effect of Blocking CXCR2 on Neutrophil Recruitment and Dextran Sodium Sulfate-Induced Colitis

  2009cited by this paper
• Increased Expression of Long Pentraxin PTX3 in Inflammatory Bowel Diseases

  2008cited by this paper
• Molecular pathogenesis of inflammatory bowel disease: Genotypes, phenotypes and personalized medicine

  2007cited by this paper
• The expanding family of interleukin‐1 cytokines and their role in destructive inflammatory disorders

  2007cited by this paper
• Intestinal innate immunity and the pathogenesis of Salmonella enteritis

  2007cited by this paper
• Chitinase 3-like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells.

  2006cited by this paper
• Caspase-1-Mediated Activation of Interleukin-1β (IL-1β) and IL-18 Contributes to Innate Immune Defenses against Salmonella enterica Serovar Typhimurium Infection

  2006cited by this paper
• Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis

  2006cited by this paper
• Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis.

  2005cited by this paper
• Imbalance between interleukin‐1 agonists and antagonists: relationship to severity of inflammatory bowel disease

  2004cited by this paper
• Collagen-binding integrin α1β1 regulates intestinal inflammation in experimental colitis

  2002cited by this paper
• Hapten-induced Colitis Is Associated with Colonic Patch Hypertrophy and T Helper Cell 2–Type Responses

  1999cited by this paper
• VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis.

  1999cited by this paper
• Expression of interleukin 1β and interleukin 1β converting enzyme by intestinal macrophages in health and inflammatory bowel disease

  1998cited by this paper
• Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines

  1998cited by this paper
• Antibodies to interleukin 12 abrogate established experimental colitis in mice

  1995cited by this paper
• Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice.

  1994cited by this paper
• Clinicopathologic study of dextran sulfate sodium experimental murine colitis.

  1993cited by this paper
• A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.

  1990cited by this paper
• A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice

  1990cited by this paper

• No citing papers are available for this paper.